Why is $XERS moving today? · SEC 8-K archive

$XERS SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $XERS: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $XERS filing catalyst

Why did $XERS trigger an AI stock catalyst alert?

$XERS triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.8/10). Headline: Xeris Biopharma Reports Q3 Revenue of $107M, Diluted EPS of $0.06, Raises FY26 and 2030 Guidance. Key points: - Total Q3 revenue rose 44% y/y to $107M, driven by 93% growth in Recorlev net revenue to >$71M. - GAAP net income reached $11.3M ($0.06 diluted EPS) vs. $0.62M in the prior-year period. - Full-year 2026 revenue guidance raised to $395M–$405M; 2030 revenue target increased to >$1B.

How did $XERS stock react after the SEC filing?

After the SEC 8-K for $XERS, observed market reaction: T0 price $10.46. Past moves do not guarantee future results.

Where can I get real-time $XERS SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $XERS via Telegram and the VIP Web Terminal from €10/month.

$XERS

$XERS – Xeris Biopharma Reports Q3 Revenue of $107M, Diluted EPS of $0.06, Raises FY26 and 2030 Guidance

Xeris Biopharma Holdings, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $XERS

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.8 / 10)

Total Q3 revenue rose 44% y/y to $107M, driven by 93% growth in Recorlev net revenue to >$71M.
GAAP net income reached $11.3M ($0.06 diluted EPS) vs. $0.62M in the prior-year period.
Full-year 2026 revenue guidance raised to $395M–$405M; 2030 revenue target increased to >$1B.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →